Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
The Physician’s Playlist: How Music Shapes Focus, Healing, and Happiness
The Physician's Playlist: How Music Shapes Focus, Healing, and Happiness Review Abstract Music has become an increasingly important tool in medical practice, influencing physician performance, patient recovery, and overall healthcare outcomes. This paper examines the role of music in healthcare settings through analysis of current
Pushing Past Procrastination: Strategies to Ignite Action and Productivity
Pushing Past Procrastination: Strategies to Ignite Action and Productivity Review Abstract Procrastination affects millions of people worldwide, creating barriers to personal and professional success. This paper examines the psychological foundations of procrastination and presents evidence-based strategies to overcome this common challenge. Through analysis of recent
IBS Next-Generation Therapies: Low FODMAP Diets, Neuromodulators, Digital Cognitive Behavioral Therapy, and Microbiome-Based Interventions
IBS Next-Generation Therapies: Low FODMAP Diets, Neuromodulators, Digital Cognitive Behavioral Therapy, and Microbiome-Based Interventions Review Abstract Background Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by abdominal pain associated with altered bowel habits. Conventional therapies often provide incomplete symptom relief, leading to
HIPAA for the Clinician, Part 4, What an OCR Investigation Looks Like
HIPAA for the Clinician, Part 4, What an OCR Investigation Looks Like will evertsen Introduction Most covered entities have a vague, uncomfortable sense that an OCR investigation is something to be avoided. Fewer still have a clear picture of what one involves, how it starts,
HIPAA for the Clinician, Part 3 Business Associate Agreements – What They Must Contain and Why Most Don’t
HIPAA for the Clinician, Part 3 Business Associate Agreements – What They Must Contain and Why Most Don’t Will evertsen Introduction Your billing company has handled your claims processing for six years. You trust them. They know your payers, your codes, your quirks. When you
What the Change Healthcare Attack Should Have Taught Every Covered Entity
What the Change Healthcare Attack Should Have Taught Every Covered Entity will evertsen Introduction On February 21, 2024, Change Healthcare went offline. The ransomware attack that took it down was not subtle. Within hours, claims processing across thousands of practices, hospitals, and pharmacies ground to
Contemporary Lipid Management in Family Practice: Risk Stratification, Coronary Artery Calcium, and Shared Decision-Making for Statin Therapy
Contemporary Lipid Management in Family Practice: Risk Stratification, Coronary Artery Calcium, and Shared Decision-Making for Statin Therapy Review Abstract Purpose: This paper examines current approaches to lipid management in family practice, focusing on risk stratification methods, the role of coronary artery calcium scoring, and implementation of
Intravenous Lipid Rescue: Why It’s Saving Lives Far Beyond Local Anesthetic Toxicity
Intravenous Lipid Rescue: Why It’s Saving Lives Far Beyond Local Anesthetic Toxicity Review Abstract Intravenous lipid emulsion therapy, originally developed as nutritional support, has emerged as a critical rescue intervention for drug toxicity cases well beyond its initial application in local anesthetic systemic toxicity. This
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden Review Abstract Lipidology is undergoing a clinically important transition from traditional cholesterol-centered assessment toward a more precise evaluation of atherogenic lipoprotein burden. Low-density lipoprotein cholesterol (LDL-C) remains a validated therapeutic target
